BT-549 cells are epithelial cells isolated in 1978 from a papillary, invasive ductal tumor which had metastasized to 3 of 7 regional lymph nodes. The cells were derived from a 72-year-old, White, female breast cancer patient.

Induction of tumorigenicity by galectin-3 in a nontumorigenic human breast-carcinoma cell-line.

In 1978, BT-549 was derived from a 72-year-old white female patient by isolating the papillary of metastasized portions of the lymph node [83]. This breast cancer cell line showed downregulation of HDAC7 and established the possibility of this gene being a tumor suppressor in TNBC [84].

To determine the biological relevance of RRS1 in breast cancer progression, the present study knocked down RRS1 in BT-549 cells using an sh-RNA construct (Fig. 2A) and the knockdown efficiency was validated by the reduced protein and mRNA levels of RRS1 (Fig. 2B-D).

BT-549 cells are a human breast cancer cell line derived from the mammary gland tissue of a 72-year-old Caucasian woman with ductal carcinoma. They are commonly utilized in cancer research to study the biology and treatment of breast cancer, particularly…

uable model for studying metastasis and tumor invasion. They exhibit several distinctive features including the presence of lipid droplets in the c. toplasm and a robust expression of the mucin-1 protein. These cells also express various oncogenes and tumor suppressor genes that are re.

From MGH/CMT as specified by cell provider: RPMI 1640 medium with 2 mM L-glutamine adjusted to contain 1.5 g/L sodium bicarbonate, 4.5 g/L glucose, 10 mM HEPES, and 1.0 mM …

Jan 5, 2022 · Cell information for BT-549. Find diseases associated with this biological target and compounds tested against it in bioassay experiments.

Visit CellMinerCDB to interactively explore available pharmacogenomics data for the breast cancer cell line: BT-549. This page was generated using the R package rcellminer 2.15.1.

Purified genomic DNA isolated from the BT-549 human breast ductal carcinoma cell line (ATCC HTB-122). This product is quantified for oncology biomarker TP53 p.R249S via NGS and ddPCR.